NCT04507503 2026-03-10
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Taiho Oncology, Inc.
Approved for marketing
Clinical Trials
13 trialsNCT04100694 2025-05-20
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus B.V.
Approved for marketing
NCT03906331 2025-01-17
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly and Company
Approved for marketing
NCT02065765 2025-01-09
International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
Eli Lilly and Company
Approved for marketing
NCT02307812 2025-01-09
Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
Eli Lilly and Company
Approved for marketing
NCT02286492 2024-09-05
Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
Taiho Oncology, Inc.
Approved for marketing
NCT00906984 2024-01-08
TheraSphere
University of California, Irvine
Approved for marketing
NCT01076517 2021-04-01
A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma
Stanford University
Approved for marketing
NCT01480128 2020-06-19
SIMPLE
The Catholic University of Korea
Approved for marketing
NCT04148092 2020-05-29
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
Deciphera Pharmaceuticals, LLC
Approved for marketing
NCT02436044 2019-08-20
HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC
Sun Yat-sen University
Approved for marketing
NCT00094029 2012-03-09
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
Pfizer
Approved for marketing
NCT00786058 2009-06-15
A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003
CONKO-Studiengruppe
Approved for marketing